TARA-002

TARA-002 is a cell therapy whose type is not stated developed by Protara Therapeutics. The sponsor describes its target as non-muscle invasive bladder cancer and lymphatic malformations, which OnCo does not yet have a target page for. The sponsor states: TARA-002 is based on OK-432, a broad immunopotentiator that is approved in Japan and Taiwan for other indications. ClinicalTrials.gov describes the intervention as: All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT07480356, plans to enrol 284 participants with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.